Investments
55Portfolio Exits
29Partners & Customers
10Service Providers
2About Philips
Philips (NYSE:PHG) is a diversified technology company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle, and Lighting. The company provides cardiac care, acute care and home healthcare, energy efficient lighting solutions, and new lighting applications, as well as male shaving and grooming and oral healthcare.
Philips Headquarter Location
Boschdijk 525
Amsterdam, 5621 JG,
Netherlands
+31 20 597 7777
Expert Collections containing Philips
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Philips in 5 Expert Collections, including Digital Health.
Digital Health
410 items
Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)
Health IT
2,853 items
Conference Exhibitors
6,062 items
Companies that will be exhibiting at CES 2018
Medical Devices
4,722 items
https://www.advamed.org/membership-join/membership-directory/ - excludes those without working websites.
Health Monitoring & Diagnostics
377 items
Companies developing technology to facilitate point-of-care (POC) diagnostic imaging. Excludes intraoperative imaging. Companies tagged as #PointOfCareImaging
Philips Web Traffic
Philips Rank
Research containing Philips
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Philips in 8 CB Insights research briefs, most recently on Feb 14, 2022.
Latest Philips News
May 16, 2022
May 16, 2022 EchoNavigator 4.0 empowers heart teams with greater control of live fusion imaging plus new anatomical modeling and transseptal puncture guidance during minimally-invasive procedures Seamless integration and communication between Philips Ultrasound System - EPIQ CVxi - and Philips Image Guided Therapy System - Azurion - supports efficient fusion-imaging workflow for minimally-invasive treatment of structural heart disease Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced at EuroPCR (17 - 20 May 2022, Paris, France) the international launch of EchoNavigator 4.0 [1], the new release of its advanced image-guided therapy solution for the treatment of structural heart disease. EchoNavigator 4.0 gives users of Philips’ EPIQ CVXi interventional cardiology ultrasound system greater control of live fusion-imaging on the company’s Image Guided Therapy System - Azurion - platform. By integrating real-time transesophageal echocardiography (TEE), which places the ultrasound transducer close to the heart, and X-ray fluoroscopy, EchoNavigator 4.0 helps interventional teams to decide, guide, treat, and confirm complex structural heart disease therapy, such as heart valve repair or replacement. The solution also includes extended anatomical intelligence models, transseptal puncture guidance to help access the left atrium and mitral valve from the right atrium, and new 3D live image fusion capabilities, including Philips’ TrueVue photo-realistic rendering and GlassVue volumetric imaging modes. It also features automatic selection of an appropriate set of multiplanar reconstruction planes (sections taken from the 3D echo heart model), with presets for common views of the aortic and mitral valves and left atrial appendage. “The latest EchoNavigator release gives us unique peri-interventional possibilities by offering a comprehensive set of automated views based on advanced 3D heart models in combination with live fusion imaging,” said Dr. Patric Biaggi, Head of Cardiac Imaging at Heart Clinic Hirslanden in Zurich, Switzerland. “This allows us to treat our patients with greater confidence and precision during every stage of the procedure.” Largely due to lifestyle choices and the aging population, structural heart disease is now commonplace in older individuals. In the USA, for example, as many as 1 in 10 people over the age of 75-years are affected by a condition known as mitral regurgitation [2], which means the mitral valve in their heart does not close properly, adversely affecting the amount of oxygenated blood that can be pumped round their body. Worldwide, around 156 million people are estimated to suffer from the condition [3]. Fortunately, in many cases treating structural heart disease can now be performed via image-guided, minimally-invasive, catheter-based procedures that impose far less trauma than open-heart surgery. Improved communication and teamwork Philips EchoNavigator helps improve communication and teamwork between echocardiographers and interventionists during image-guided therapy by automatically fusing together echocardiography ultrasound and X-ray images, while also enhancing understanding of the relationship between X-ray and ultrasound in an intuitive way that helps interventional teams to complete procedures with greater safety, confidence, and clarity. “Cardiology teams across the world are facing increasing numbers of complex structural heart disease cases and are seeking new ways to deliver effective high-quality care despite staffing shortages,” said Karim Boussebaa, General Manager of Image Guided Therapy Systems at Philips. “By helping echocardiographers and interventionists to work together in even more highly coordinated ways, this new release of EchoNavigator is an important step forward in boosting patient throughput, making more efficient use of time and resources, and achieving positive cardiovascular care outcomes.” Greater control for echocardiographers EchoNavigator 4.0 puts greater control of imaging in the hands of the echocardiographer via the EPIQ ultrasound platform’s touch screen, including the ability to fuse and annotate echocardiography and X-ray fluoroscopy images. Anatomical features can be identified either manually or automatically, with anatomical markers and annotations applied to one modality automatically transposed to the other. Live fusion images, markers, and annotations are immediately visible to interventional cardiologists via the Azurion platform’s FlexVision Pro monitor to help guide catheterization and therapy device deployment. Extended automatic modeling and transseptal puncture guidance Additional context and guidance are provided by EchoNavigator’s automated 3D anatomical modeling capabilities. These include models for the mitral valve and its leaflets, and transseptal area models to help identify the optimum zone in the wall separating the right and left atrium where the septum can be punctured to catheterize the left atrium and mitral valve. These 3D modeling capabilities also allow EchoNavigator 4.0 to automatically select an optimal set of multiplanar reconstruction planes, with presets for optimally viewing the aortic and mitral valves and left atrial appendage. Enhanced fusion imaging with Cardiac TrueVue and TrueVue Glass rendering EchoNavigator 4.0’s fusion imaging capabilities have been further enhanced by the ability to fuse live X-ray fluoroscopy images with live TrueVue and TrueVue Glass rendered echocardiography images to more easily visualize positioning and device-tissue interactions. Philips TrueVue 3D echo rendering improves visualization of anatomical structures and devices, while TrueVue Glass with Color allows interventionists to view the location of regurgitant blood flow across a heart valve. With its long history of leadership in cardiology innovation, informed by continuous collaboration with leading clinical partners, Philips is uniquely positioned to deliver integrated solutions that span the care pathway to help solve cardiology’s daily challenges and provide better heart care with greater efficiency . [1] Philips EchoNavigator 4.0 is not yet available in all markets, e.g not available in USA or China. [2] Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association https://pubmed.ncbi.nlm.nih.gov/20019324/ . [3] Dziadzko V, Clavel MA, Dziadzko M, et al. Outcome and undertreatment of mitral regurgitation: a community cohort study. Lancet. 2018;391(10124):960-969. doi:10.1016/S0140-6736(18)30473-2 https://pubmed.ncbi.nlm.nih.gov/29536860/ . For further information, please contact: Joost Maltha About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter . Attachment
Philips Investments
55 Investments
Philips has made 55 investments. Their latest investment was in B-SOFT as part of their Corporate Minority - P2P - II on May 5, 2022.
Philips Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
5/13/2022 | Corporate Minority - P2P - II | B-SOFT | $180M | Yes | 1 | |
2/23/2022 | Series A | CVAid Medical | $4M | Yes | RadBioMed, and Sanara Ventures | 5 |
8/24/2021 | Series B | DiA Imaging Analysis | $14M | Yes | 5 | |
8/20/2021 | Series A - III | |||||
8/2/2021 | Series C |
Date | 5/13/2022 | 2/23/2022 | 8/24/2021 | 8/20/2021 | 8/2/2021 |
---|---|---|---|---|---|
Round | Corporate Minority - P2P - II | Series A | Series B | Series A - III | Series C |
Company | B-SOFT | CVAid Medical | DiA Imaging Analysis | ||
Amount | $180M | $4M | $14M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | RadBioMed, and Sanara Ventures | ||||
Sources | 1 | 5 | 5 |
Philips Portfolio Exits
29 Portfolio Exits
Philips has 29 portfolio exits. Their latest portfolio exit was ALung Technologies on May 05, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
5/5/2022 | Acquired | 2 | |||
7/6/2021 | Divestiture | 1 | |||
5/5/2021 | Divestiture | Philips Lifeline | 3 | ||
Date | 5/5/2022 | 7/6/2021 | 5/5/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | Divestiture | Divestiture | ||
Companies | Philips Lifeline | ||||
Valuation | |||||
Acquirer | |||||
Sources | 2 | 1 | 3 |
Philips Acquisitions
44 Acquisitions
Philips acquired 44 companies. Their latest acquisition was Vesper Medical on December 14, 2021.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
12/14/2021 | Series B | $52.46M | Acquired | 5 | ||
11/8/2021 | Series A | $21.4M | Acquired | 4 | ||
1/19/2021 | Growth Equity | Acquired - II | 23 | |||
12/18/2020 | Other Venture Capital | |||||
8/27/2020 | Debt |
Date | 12/14/2021 | 11/8/2021 | 1/19/2021 | 12/18/2020 | 8/27/2020 |
---|---|---|---|---|---|
Investment Stage | Series B | Series A | Growth Equity | Other Venture Capital | Debt |
Companies | |||||
Valuation | |||||
Total Funding | $52.46M | $21.4M | |||
Note | Acquired | Acquired | Acquired - II | ||
Sources | 5 | 4 | 23 |
Philips Partners & Customers
10 Partners and customers
Philips has 10 strategic partners and customers. Philips recently partnered with Prisma Health on April 4, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
4/28/2022 | Partner | United States | Royal Philips and Prisma Health Enter Multi-Year Agreement Royal Philips , a leader in health technology , and Prisma Health , South Carolina 's largest non-profit healthcare system , have entered into a multi-year agreement to help the health system achieve enterprise interoperability , standardize patient monitoring , and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance . | 2 | |
4/28/2022 | Partner | United States | Amsterdam , the Netherlands and South Carolina , USA -- Royal Philips , a global leader in health technology , and Prisma Health , South Carolina 's largest non-profit healthcare system , today announced they have entered into a multi-year agreement to help the health system achieve enterprise interoperability , standardize patient monitoring , and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance . | 3 | |
4/27/2022 | Partner | United States | ClearPoint Neuro , Inc. is partnered with approximately 40 biologics/pharmaceutical companies and academic centers , providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide . | 1 | |
4/12/2022 | Partner | ||||
3/25/2022 | Licensor |
Date | 4/28/2022 | 4/28/2022 | 4/27/2022 | 4/12/2022 | 3/25/2022 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Licensor |
Business Partner | |||||
Country | United States | United States | United States | ||
News Snippet | Royal Philips and Prisma Health Enter Multi-Year Agreement Royal Philips , a leader in health technology , and Prisma Health , South Carolina 's largest non-profit healthcare system , have entered into a multi-year agreement to help the health system achieve enterprise interoperability , standardize patient monitoring , and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance . | Amsterdam , the Netherlands and South Carolina , USA -- Royal Philips , a global leader in health technology , and Prisma Health , South Carolina 's largest non-profit healthcare system , today announced they have entered into a multi-year agreement to help the health system achieve enterprise interoperability , standardize patient monitoring , and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance . | ClearPoint Neuro , Inc. is partnered with approximately 40 biologics/pharmaceutical companies and academic centers , providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide . | ||
Sources | 2 | 3 | 1 |
Philips Service Providers
2 Service Providers
Philips has 2 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
XMS Capital Partners | Acquired Unit | Investment Bank | Financial Advisor |
Service Provider | XMS Capital Partners | |
---|---|---|
Associated Rounds | Acquired Unit | |
Provider Type | Investment Bank | |
Service Type | Financial Advisor |
Partnership data by VentureSource
Philips Team
174 Team Members
Philips has 174 team members, including current Chief Executive Officer, Neil Mesher.
Name | Work History | Title | Status |
---|---|---|---|
Neil Mesher | Chief Executive Officer | Current | |
Matthew East | Chief Financial Officer | Current | |
Joseph Frassica | Jackson Health System, University of Miami, University of Massachusetts Medical School, and Massachusetts General Hospital | Chief Medical Officer | Current |
Chip Truwit MD FACR | Chief Medical Officer | Current | |
John Payne | Senior Vice President | Current |
Name | Neil Mesher | Matthew East | Joseph Frassica | Chip Truwit MD FACR | John Payne |
---|---|---|---|---|---|
Work History | Jackson Health System, University of Miami, University of Massachusetts Medical School, and Massachusetts General Hospital | ||||
Title | Chief Executive Officer | Chief Financial Officer | Chief Medical Officer | Chief Medical Officer | Senior Vice President |
Status | Current | Current | Current | Current | Current |
You May Also Like
Paige delivers AI-powered digital diagnostics and biomarkers for pathologists, oncologists, and the R&D community worldwide, while also working closely with biopharma companies to create custom diagnostic solutions and drug development technologies to improve patient care. The firm's target customers include pathologists, hospital leads/chairs as well as life sciences research and translational teams.

Sectra (STO: SECTB) develops and sells IT systems and services for radiology and other image-intensive departments, orthopaedics and rheumatology.
12 SIGMA is a biotechnology company that integrates artificial intelligence and deep learning into modern medical image diagnosis and medical data analysis. 12SIGMA is based in Beijing and San Diego.

Proscia is a software company focused on transforming cancer research and diagnosis. With the company's Concentriq digital pathology platform and pipeline of AI algorithms, laboratories are leveraging new kinds of data to improve patient outcomes and accelerate discoveries.

Ligence develops an artificial intelligence-powered automated heart ultrasound analysis system.

mediaire offers (neuro)radiologists a detailed brain volumetry and lesion report for each patient by an automated, AI-based MRI analysis within just five minutes locally in their center. The radiologist can therefore talk through the MR report within the same patient appointment. Its first product family with mdbrain & mdspine is already certified as a medical device in Europe according to DIN EN ISO 13485:2016.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.